In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma
about
Potential role for interleukin-10 in the immunosuppression associated with kala azarA role for IgG immune complexes during infection with the intracellular pathogen Leishmania.Immunoregulation in human American leishmaniasis: balancing pathology and protectionProtection and pathology during parasite infection: IL-10 strikes the balanceB7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infectionsAbortive T follicular helper development is associated with a defective humoral response in Leishmania infantum-infected macaquesImmunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasisRole of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasisImmunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccinesDifferential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapySwitch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and PentostamDistribution of IgG subclasses in antimonial unresponsive Indian kala-azar patientsA curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapyTherapeutic enhancement of protective immunity during experimental leishmaniasisRestoration of IFNγR subunit assembly, IFNγ signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterolIdentification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model systemGrowth factor and Th2 cytokine signaling pathways converge at STAT6 to promote arginase expression in progressive experimental visceral leishmaniasisA novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral LeishmaniasisMacrophage and T-cell gene expression in a model of early infection with the protozoan Leishmania chagasi.Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasisCytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections.Alcoholic Fractions F5 and F6 from Withania somnifera Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis.Mapping of specific and promiscuous HLA-DR-restricted T-cell epitopes on the Plasmodium falciparum 27-kilodalton sexual stage-specific antigen.Importance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis.Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance.Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential induction of a regulatory T helper type 2 lymphocyte subset.Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis.Clinical and experimental advances in treatment of visceral leishmaniasis.Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania sppRole of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression.Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.Dual immune modulatory effect of vitamin A in human visceral leishmaniasis.Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasisBalancing immunity and pathology in visceral leishmaniasis.Transcriptional profiling of the spleen in progressive visceral leishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes.
P2860
Q24594397-E37A5A7B-704A-48B5-91AC-A8714497DF65Q25256801-C18B71CD-7692-4BBD-923A-BB0B7F625AD0Q26850280-C86D8CC1-C072-4250-9E1A-5DB9D6D10020Q27005837-2106719E-3D0D-4D2A-BEFA-749E7B6CF9BEQ27317015-E9FBD92C-812B-474A-A46D-7BC1A415EA05Q27326637-FE4ADED3-F92B-496D-9219-D1CD8BA53284Q28137699-194377AD-7EC8-497E-BBC5-F63EA6CD1266Q28139641-B65B459E-C071-4A7D-9A30-038BCB04B52CQ28273639-53F3BE19-341D-4E25-BBCA-3C5BB674EBC8Q28343709-77E86611-EDDF-438A-9CDD-3370C97B0567Q28368077-8C49F3A0-7BF7-441D-A74E-F5A55212C272Q28369347-DFE0233C-8973-401A-A397-3808B1F054C4Q28474921-5CCCC020-FCF3-4082-BCD4-244A1E7DCA06Q28476803-5F22B88A-28B5-498E-A22A-36FBAF9C5926Q28476834-53004EB3-D53D-4342-87AE-48957E18C897Q28477163-EC758206-3678-4530-B423-2516306C1E59Q28540097-E712D17D-50D9-4B8D-8708-13A70343AD35Q30833358-203C0590-DC37-4943-8617-B31D59FC6039Q31060208-62F0378D-6473-4F29-BCFF-99CB8A001A86Q33346267-138B12BE-807C-4272-9A92-B72FEB1DDE4EQ33559747-D3268947-2B29-48B0-A51E-185375E4B6D3Q33624814-AD8A2DE6-81A4-4863-8C02-7BD962751DB2Q33665654-C91CF540-B673-497C-95BB-FD548EE378FEQ33757364-54B83BBE-AF86-47A1-9516-EACA99034005Q33762670-DE9D039B-0E04-46B5-A855-3827B34ECB61Q33849243-81476346-0AE0-4C28-97CB-44353C50F6D3Q33883498-C02A9CFC-08A0-4BCB-9BCE-30DDF652BCB8Q33903999-F64F5362-E13F-4C6B-A581-33AF48CF75D4Q33963990-30FB7801-9F97-4346-A604-5D183B2D474FQ33982648-9F85D342-C6E3-449E-870A-F0A554C71192Q34054948-9A903AB8-7016-4FDD-A4EA-C27D2475D067Q34121668-19922D43-7CB2-4DA7-AAFE-F2D60AAD1E26Q34126859-4FEB15A1-B435-4653-8C4A-D1AC36082381Q34139938-EC4FD355-CEE7-4A57-A408-EE2073E5CE24Q34149280-8DB7F231-04F1-435C-998C-CEAAEBF21CD2Q34181985-785BF71D-97CC-450E-B179-62BF4808AE7AQ34275996-BAB9A4EC-1AD4-4BD7-B8E7-69AAA68E4430Q34521577-1AC71569-F87B-4C32-982B-FBC8D993156AQ34587432-271092CF-EE92-4129-A824-37CA79792773Q34617155-3D09730A-25D2-4E5A-84FA-76E899CB8F31
P2860
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma
description
1993 nî lūn-bûn
@nan
1993 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@ast
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@en
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@nl
type
label
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@ast
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@en
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@nl
prefLabel
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@ast
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@en
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@nl
P2093
P2860
P921
P3181
P356
P1476
In vivo cytokine profiles in p ...... leukin-10 and interferon-gamma
@en
P2093
A M Kordofani
F A Hashim
S H el-Safi
T B Nutman
P2860
P304
P3181
P356
10.1172/JCI116372
P407
P577
1993-04-01T00:00:00Z